PMV Pharmaceuticals, Inc.
NASDAQ:PMVPBiotechnology
+$0.04 today
- Market cap
- $65.06M
- Beta
- 1.36
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$1.47
Volume 0.43M
Average 0.38M
PMVP Total Liabilities
Everything the company owes to creditors and other parties.
PMV Pharmaceuticals, Inc.NASDAQ: PMVP
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 18.2% from a year ago
Total liabilities stood at $8.6M at the end of Q1 FY2026, down 18.2% from a year earlier and down 27.5% from the prior quarter. Over 3 fiscal years it compounded at -21.3% a year.
Context
- Total liabilities amounted to 8.9% of total assets at the end of Q1 FY2026, up 2.7 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -18.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 11.85M USD
- Year-over-year change
- -22.1%
- 4-year CAGR
- -15.3%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.85M | -22.1% |
| FY2024 | 2024-12-31 | 15.21M | -42.5% |
| FY2023 | 2023-12-31 | 26.46M | +9.0% |
| FY2022 | 2022-12-31 | 24.28M | +5.5% |
| FY2021 | 2021-12-31 | 23.01M | — |
Total Liabilities vs competitors
How PMVP compares with its peers on the latest reported figures
- PMVP's Mar 2026 total liabilities of $8.6M is the lowest of the 9 companies compared; the peer median is $33.09M.
- Its year-over-year change of -18.2% is the 7th highest of 9, against a peer median of +1.5%.
- Total liabilities amounts to 8.9% of total assets for PMVP, versus a peer median of 37.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CBUSCibus, Inc. | Mar 2026 | $288.72M | +10.6% | +165.2% | 89.1% |
| Mar 2026 | $105.07M | -14.2% | +2.0% | 52.0% | |
| Mar 2026 | $85.94M | -23.9% | +31.5% | 47.7% | |
| Mar 2026 | $38.51M | +49.2% | +29.7% | 20.3% | |
| Mar 2026 | $27.67M | +5.1% | +11.8% | 59.6% | |
| Mar 2026 | $21.91M | -2.1% | +3.1% | 27.5% | |
| Mar 2026 | $16.63M | +217.4% | -15.6% | 7.1% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $12.32M | -22.8% | +17.0% | 11.4% |
| Mar 2026 | $8.6M | -18.2% | -21.3% | 8.9% | |
| Peer median (excluding PMVP) | $33.09M | +1.5% | +14.4% | 37.6% | |
Competitors are the stored peer set for PMVP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 172.47M | 108.3M | 37.71M | 40.88M | 37.98M |
| Short-term Investments | 124.7M | 132.76M | 165.35M | 128.58M | 74.96M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 822K | 5.95M | 4.35M | 6.2M | 2.28M |
| Total Current Assets | 301.29M | 247.01M | 207.41M | 175.66M | 115.23M |
| Property, Plant & Equipment (Net) | 13.15M | 20.49M | 19.05M | 1.55M | 1.04M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 16.91M | 2.5M | 25.51M | 13.84M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 221K | 313K | 190K | 235K | 297K |
| Total Non-current Assets | 30.28M | 23.3M | 44.74M | 15.63M | 1.34M |
| Total Assets | 331.57M | 270.31M | 252.15M | 191.29M | 116.56M |
| Account Payables | 3.19M | 3M | 3.24M | 6.58M | 3.16M |
| Short-term Debt | 0 | 0 | 0 | 352K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.8M | 2.9M | 4.5M | 5.01M | 4.53M |
| Total Current Liabilities | 12.22M | 10.83M | 14.03M | 14.37M | 11.42M |
| Long-term Debt | 0 | 0 | 0 | 0 | 435K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 10.79M | 13.45M | 12.43M | 838K | 435K |
| Total Liabilities | 23.01M | 24.28M | 26.46M | 15.21M | 11.85M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (167.73M) | (241.04M) | (310M) | (368.71M) | (446.45M) |
| Accumulated OCI | (78K) | (445K) | 224K | 139K | 84K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 308.56M | 246.03M | 225.69M | 176.08M | 104.71M |
| Total Debt | 11.19M | 13.98M | 13.29M | 1.19M | 838K |
| Net Debt | (161.27M) | (94.32M) | (24.42M) | (39.69M) | (37.15M) |
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
Intrinsic Alpha fair value
Locked
Current Price
$1.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.